Viruses Surpass Treatments warns report
A recent international report warns of a significant gap between the rapid development and spread of dangerous viruses and the world's capacity to develop effective antiviral drugs. Currently, drug development plans are still insufficient to address potential threats. Among 14 viral families considered the most threatening, only 6 have ongoing clinical trial indicators, with no compounds available for three of the families. Additionally, the development of new drugs can take up to 4-5 years, reflecting a substantial delay in meeting global health needs when new viruses emerge. This issue is exemplified by the ongoing Ebola outbreak in Congo, which highlights the urgent need to develop ready-to-use treatments in advance rather than relying on research during crises. The focus is now on developing broad-spectrum antiviral drugs that can target multiple viruses within a family, along with intensified efforts to fund new research and improve preparedness for future pandemics, especially considering figures indicating that approximately 400 million people worldwide are annually affected by dengue fever.
Notice: This Is an AI-Generated Summary
Comments (0)